Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.67 |
| ▸ | LMNA | P02545 | 6/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.67 |
| ▸ | MEN1 | O00255 | 4/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | HTT | P42858 | 8/20 | 0.65 |
| ▸ | MITF | O75030 | 4/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.65 |
| ▸ | USP2 | O75604 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CASP1 | P29466 | 1/20 | 0.64 |
| ▸ | BLM | P54132 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 5/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11037676 | 0.84 | MEN1 (0.55) | MAPTLMNAKMT2AALDH1A1MEN1 | |
| SCHEMBL2462643 | 0.80 | MAPT (1.00) | MAPTLMNAKMT2AALDH1A1MEN1 | |
| SCHEMBL16887864 | 0.79 | MAPT (0.63) | MAPTLMNAKMT2AALDH1A1MEN1 | |
| SCHEMBL17249965 | 0.79 | MAPT (1.00) | MAPTLMNAKMT2AALDH1A1MEN1 | |
| SCHEMBL6506683 | 0.78 | MAPT (1.00) | MAPTLMNAKMT2AALDH1A1MEN1 | |
| SCHEMBL29633261 | 0.78 | MAPT (1.00) | MAPTLMNAKMT2AALDH1A1MEN1 | |
| SCHEMBL31087717 | 0.77 | HSP90AA1 (1.00) | MAPTLMNAKMT2AALDH1A1MEN1 | |
| SCHEMBL6190569 | 0.77 | HSP90AA1 (1.00) | MAPTLMNAKMT2AALDH1A1MEN1 | |
| SCHEMBL17918976 | 0.77 | S100A4 (0.69) | MAPTKMT2AALDH1A1MEN1KDM4E | |
| SCHEMBL27164642 | 0.77 | MEN1 (0.53) | MAPTLMNAKMT2AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11919858-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2024-03-05 | — | — | US | disclosed |
| US-11919858-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2024-03-05 | — | — | US | disclosed |
| US-11084786-B2 | Compounds and pharmaceutical composition associated with ubiquitination-proteasome system | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2021-08-10 | — | — | US | disclosed |
| US-20200385344-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2020-12-10 | — | — | US | disclosed |
| US-10745350-B2 | Compounds and pharmaceutical composition associated with ubiquitination-proteasome system | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2020-08-18 | — | — | US | disclosed |
| US-20200148643-A1 | AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2020-05-14 | — | — | US | disclosed |
| US-20190144383-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2019-05-16 | — | — | US | disclosed |
| WO-2015172076-A1 | NAPHTHAQUINONE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2015-11-12 | — | — | WO | disclosed |
| EP-1256576-B1 | FUSED IMIDAZOLIUM DERIVATIVES | YAMANOUCHI PHARMA CO LTD (JP) | 2005-06-15 | — | — | EP | disclosed |
| WO-2005016264-A2 | DIAMINE DERIVATIVES OF QUINONE AND USES THEREOF | AVALON PHARMACEUTICALS (US) | 2005-02-24 | — | — | WO | disclosed |
| WO-2005016000-A1 | DERIVATIVES OF CYCLIC QUINONE AND USES THEREOF | AVALON PHARMACEUTICALS (US) | 2005-02-24 | — | — | WO | disclosed |
| WO-2005013903-A2 | DERIVATIVES OF SUBSTITUTED QUINONE AND USES THEREOF | AVALON PHARMACEUTICALS (US) | 2005-02-17 | — | — | WO | disclosed |
| US-20050032794-A1 | Diamine derivatives of quinone and uses thereof | CLINICAL DATA, INC. | 2005-02-10 | — | — | US | disclosed |
| US-6734203-B2 | ANTI-CANCERS AND ANTITUMOR AGENTS | ASTELLAS PHARMA INC. (JP) | 2004-05-11 | — | — | US | disclosed |
| US-20030114508-A1 | Fused imidazolium derivatives | ASTELLAS PHARMA INC. (JP) | 2003-06-19 | — | — | US | disclosed |
| EP-1256576-A1 | FUSED IMIDAZOLIUM DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2002-11-13 | — | — | EP | disclosed |
| EP-0240047-B1 | FUNGICIDES | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1991-01-02 | — | — | EP | disclosed |
| EP-0240047-A1 | Fungicides | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1987-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144383-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM | PSMC1, PSME3, PSMB1 | MAPT 308/4885LMNA 3480/4885KMT2A 1683/4885 |
| US-20200148643-A1 | AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | UBQLN1, UBQLN2, PSMB1 | MAPT 406/4885LMNA 2100/4885KMT2A 1444/4885 |
| US-10745350-B2 | Compounds and pharmaceutical composition associated with ubiquitination-proteasome system | PSMC1, PSME3, PSMB1 | MAPT 308/4885LMNA 3480/4885KMT2A 1683/4885 |
| US-20030114508-A1 | Fused imidazolium derivatives | TP53, HRAS, BCOR | MAPT 4795/4885LMNA 3417/4885KMT2A 2218/4885 |
| US-11084786-B2 | Compounds and pharmaceutical composition associated with ubiquitination-proteasome system | PSMC1, PSME3, PSMB1 | MAPT 308/4885LMNA 3480/4885KMT2A 1683/4885 |
| US-20200385344-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITION ASSOCIATED WITH UBIQUITINATION-PROTEASOME SYSTEM | PSMC1, PSME3, PSMB1 | MAPT 308/4885LMNA 3480/4885KMT2A 1683/4885 |
| US-11919858-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | UBQLN1, PSMB1, UBQLN2 | MAPT 1163/4885LMNA 1057/4885KMT2A 1688/4885 |
| US-20050032794-A1 | Diamine derivatives of quinone and uses thereof | NQO1, DPYD, NQO2 | MAPT 3849/4885LMNA 3778/4885KMT2A 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.